Immunotherapy may change how your body processes other drugs
NCT ID NCT07389525
First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This study will test whether immunotherapy drugs (immune checkpoint inhibitors) change how the liver processes other medications. About 80 adults with various cancers who are starting immunotherapy will take a low-dose cocktail of 7 common drugs. Researchers will measure drug levels in the blood to see if interactions occur, which could explain some side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- immune checkpoint inhibitors (immunotherapy) and a cocktail of 7 FDA-approved drugs
- What this could lead to
- If successful, this could help doctors predict and prevent dangerous drug interactions in cancer patients on immunotherapy.
- What could go wrong
- This is a very early, small study (80 people) that only measures drug levels, not treatment outcomes. Results may not apply to all patients or drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new protein drug shield kids with cancer from dangerous infections?
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.